Saturday 17 October 2026 Export ASTH’s income statement to Excel — free account

Astrana Health, Inc.

Astrana Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 56.4% from fiscal 2024. In the quarter to June 2026, revenue grew 48.5%, EPS grew 110.5%, free cash flow fell 67.7% and total debt rose 126.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

36.81 1.22 −3.21%

Follow ASTH

Alert me

Market cap: $1.9B
P/E: 44.3×
Fwd P/E: 29.7×
Dividend yield: —
F-score: 4/9
Altman Z: 2.39
Beneish M: −2.19
Dividend safety: 50/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 20.13%

Capital & Financial Ratios $m

Market Cap 1,890.00

Revenue 3,844.19

Net Income 39.22

Free Cash Flow 94.38

Net Debt 535.71

Current Ratio 1.23

Debt/Equity 1.11

P/E ratio 44.35

Fwd P/E 29.70

P/S ratio 0.47

P/B ratio 2.15

Past 5Y EPS Growth (14.55%)

This Y EPS Growth 206.52%

Next Y EPS Growth 40.49%

Next Y revenue growth 25.15%

Next 5Y EPS Growth 78.99%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 69.23%

10-year low 10-year high

P/S against its own 10 years 6.74%

10-year low 10-year high

P/B against its own 10 years 15.29%

10-year low 10-year high

EV/Sales against its own 10 years 7.69%

10-year low 10-year high

EV/FCF against its own 10 years 50.02%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	296	288	429	401
Receivables	148	325	403	489
Inventory	—	—	—	—
Other	—	—	—	—
	462	638	863	919

	2023	2024	2025	Q'26
Payables	60	106	196	246
ST’ Debt	20	9	48	54
Other	19	27	24	17
	219	366	615	748

Compound Annual Growth %

	10y	5y	3y
Sales	26.39%	35.87%	40.62%
Cash Flow	17.99%	19.94%	11.74%
Earnings	6.98%	(9.81%)	(20.75%)
Book Value	24.65%	19.11%	13.38%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	965	973	—	—	—
’25	620	655	956	951	3,182
’24	404	486	479	665	2,035
’23	337	348	348	353	1,387
’22	263	270	317	294	1,144
’21	176	176	227	195	774
’20	165	165	180	177	687

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	68	33	—	—	—
’25	17	91	10	(3)	115
’24	6	23	34	(11)	52
’23	8	26	15	19	68
’22	24	9	(36)	85	82
’21	10	21	51	(12)	70
’20	(9)	22	36	(3)	46

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	64	29	—	—	—
’25	14	89	7	(6)	104
’24	6	20	32	(13)	44
’23	(7)	23	11	12	40
’22	7	8	(39)	84	59
’21	10	14	42	(15)	51
’20	(10)	22	36	(3)	45

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.29	0.40	—	—	—
’25	0.14	0.19	0.01	0.12	0.46
’24	0.31	0.40	0.33	(0.15)	0.90
’23	0.31	0.28	0.47	0.26	1.29
’22	0.31	0.25	0.56	(0.06)	1.08
’21	0.30	0.28	0.74	0.30	1.63
’20	0.11	0.19	0.45	0.27	1.01

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.41	5.65	13.01	13.02	9.27	18.26	26.89	27.55	31.34	20.12	Analyst estimates 2026–2028 Powerpack
	High	9.00	25.00	30.00	23.26	19.68	133.23	74.01	40.81	63.20	39.97
People
People	Employees	150	493	492	555	630	1,133	1,362	1,800	1,900	3,000
	Revenue/emp, $m	0.00	0.72	1.06	1.01	1.09	0.68	0.84	0.77	1.07	1.06
Income, $m
Income, $m	Revenue	306	356	520	561	687	774	1,144	1,387	2,035	3,182
	Gross margin, %	16.72	23.26	30.54	16.56	21.53	22.97	17.43	15.50	13.34	10.73
	EBT	19	50	83	26	178	78	87	90	81	40
	EBT margin, %	6.16	13.95	15.89	4.61	25.97	10.05	7.57	6.48	3.97	1.24
	Net income	10	46	60	18	122	46	46	58	50	24
	Depreciation	18	22	23	21	20	19	18	19	30	50
Per share, $
Per share, $	Revenue	12.40	13.96	15.81	16.15	18.81	17.66	25.44	29.79	42.75	64.83
	Earnings	0.41	0.90	0.33	0.41	1.04	1.69	1.09	1.30	0.91	0.46
	Cash flow	0.89	2.03	0.78	0.39	1.26	1.60	1.83	1.47	1.10	2.34
	Capex	(0.13)	(0.08)	(0.04)	(0.03)	(0.03)	(0.44)	(0.51)	(0.61)	(0.17)	(0.21)
	Free cash flow	0.75	1.95	0.74	0.36	1.23	1.17	1.32	0.85	0.93	2.13
	Book value	3.55	6.43	5.52	5.54	9.06	10.36	12.10	13.25	15.06	16.16
	Shares, m	25	26	33	35	37	44	45	47	48	49
Valuation, ×
Valuation, ×	P/E	0.00	13.37	60.15	46.03	17.40	43.74	25.93	29.38	35.03	53.93
	P/S	0.00	1.59	1.26	1.14	0.97	4.16	1.11	1.30	0.74	0.38
	P/B	0.00	3.73	3.60	3.32	2.02	7.09	2.33	2.93	2.09	1.53
	EV/Sales	0.00	1.30	1.07	1.18	0.94	4.03	1.03	1.29	0.81	0.57
	EV/FCF	0.00	10.03	22.96	52.35	14.38	61.02	19.98	45.05	37.29	17.48
Cash, $m
Cash, $m	Operating cash flow	22	52	25	14	46	70	82	68	52	115
	Capex	(3)	(2)	(1)	(1)	(1)	(19)	(23)	(29)	(8)	(10)
	Free cash flow	19	50	24	13	45	51	59	40	44	104
Balance, $m
Balance, $m	Working capital	31	35	101	224	224	290	280	243	273	248
	Total debt	0	6	14	242	241	185	205	279	435	1,039
	Net debt	(57)	(113)	(94)	22	(20)	(102)	(88)	(17)	146	609
	Shareholders’ equity	88	164	182	192	331	454	544	617	717	793
Returns, %
Returns, %	ROA	6.20	10.09	2.16	2.27	4.87	8.18	4.93	6.39	3.77	1.26
	ROIC	23.76	42.70	63.47	9.44	16.17	17.42	14.29	8.82	6.47	3.50
	ROE	26.89	33.62	6.27	7.55	14.41	17.56	9.05	10.46	6.47	2.98

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MD Pediatrix Medical Group, Inc.	$2.3B	13.1×	11.3×	+4.04% (above 0%: growing)	+6.52% (above 0%: growing)	−6.56% (below 0%: shrinking)	27.16%	11.67%	Compare
ADUS Addus HomeCare Corporation	$2.2B	20.4×	14.9×	+8.01% (above 0%: growing)	+24.17% (above 0%: growing)	+81.74% (above 0%: growing)	32.21%	10.32%	Compare
SGRY Surgery Partners, Inc.	$1.9B	— (loss-making)	— (loss-making)	+2.75% (above 0%: growing)	n/m	−60.63% (below 0%: shrinking)	22.41%	12.78%	Compare
ASTH Astrana Health, Inc.	$1.9B	44.3×	29.7×	+48.52% (above 0%: growing)	+110.53% (above 0%: growing)	−67.74% (below 0%: shrinking)	10.70%	3.53%
ARDT Ardent Health, Inc.	$1.7B	21.7×	7.7×	−1.40% (below 0%: shrinking)	−76.92% (below 0%: shrinking)	+121.70% (above 0%: growing)	100.00%	3.44%	Compare
SNDA Sonida Senior Living, Inc.	$1.7B	— (loss-making)	— (loss-making)	+122.02% (above 0%: growing)	n/m	−291.70% (below 0%: shrinking)	34.97%	(2.63%)	Compare
CMPS COMPASS Pathways PLC Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−4.18% (below 0%: shrinking)	—	0.00%	Compare
AMN AMN Healthcare Services Inc	$1.6B	15.0×	31.2×	+2.29% (above 0%: growing)	n/m	−389.43% (below 0%: shrinking)	30.58%	4.00%	Compare
AGL Agilon Health, Inc.	$1.5B	— (loss-making)	— (loss-making)	+7.15% (above 0%: growing)	n/m	−50.19% (below 0%: shrinking)	7.17%	0.79%	Compare
Median of peers	$1.7B	17.7×	13.1×	+4.04%	+6.52%	−28.37%	30.58%	3.72%

All 55 Medical Care Facilities stocks →

Astrana Health, Inc. (ASTH) key facts

Strength: Astrana Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 56.4% from fiscal 2024.
Astrana Health, Inc. (ASTH) is a Medical Care Facilities company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ASTH traded at $36.81, a market capitalization of $1.9 billion.
Return on equity was 2.98% and debt-to-equity 1.11.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 2.39 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.